EN DE
Watch HeartSciences Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

HeartSciences Inc. (HSCS) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of HeartSciences Inc. stock $1.79, price $2.13, that is 15.8% below the price, quality 17 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US42254E1047

HI HeartSciences Inc. logo Thin data Nov 10, 2026

HeartSciences Inc.

HSCS · US

Expensive (fair value 16% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Negative equity (buybacks among others) 
Mixed vs. peers (2/4) 
Fair value $1.79 · Overvalued 
Quality 17/100 
Weak Growth (revenue 5y −29.9 %/yr in USD) 
Negative free cash flow 
Narrow moat 12/100 · thin data
Thin data 
Estimate
Watch HeartSciences Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$340.00 $0.0170 Fair Value $1.79 Jun 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

53‑month range $0.0170 – $340.00 · fair‑value band $1.34 – $2.23 · the $2.13 price screens above the $1.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow HeartSciences in your weekly email

Every Wednesday you see whether HeartSciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence.

Show moreShow less

It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform.

The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

Stock analysis

HeartSciences Inc. (HSCS) currently trades at $2.13, while our estimate is $1.79, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.34 (bear) to $2.23 (bull), the price of $2.13 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

HeartSciences Inc. reported revenue of $4.3K in FY2026 versus $14.4K in FY2022, a compound −26.0%/yr. Reported net income was −$9.1M in FY2026.

Key figures

Market cap $10.3M Micro · EPS (TTM) $−3.21 · Return on equity −1,852% · Return on assets (EBIT) −135% (5-year average) · Operating margin −139,957% · Revenue (TTM) $4.5K · Revenue growth (YoY) +10.5% · Free cash flow −$7.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −16%, HSCS screens richer than that median.

Fair Value

Bear $1.34 Fair Value $1.79 Bull $2.23
Price $2.13 · Downside -15.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 17/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 1
How calm the share price moves, does not count
Price momentum 47
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.9%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,030.2% (2021) → −194,787.4% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

HSCS screens overvalued: fair value 16% below the price. Compare with Abbott Laboratories, →

Compare HeartSciences Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/4 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 17 · Bottom 25%
Fair Value upside −15.8% · Below median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −0.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 10.5% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 17
FUTURE (revenue growth)53 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $340.60 +10% vs HSCS
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs HSCS
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs HSCS
DexCom, Inc DXCM $83.33 $91.66 +10% vs HSCS
STERIS plc STE $264.32 $281.90 +7% vs HSCS
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs HSCS
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs HSCS
Medtronic plc MDT $102.86 $74.90 −27% vs HSCS
Abbott Laboratories, ABT $108.52 $75.28 −31% vs HSCS
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs HSCS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HeartSciences Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HeartSciences Inc. Fair Value". https://www.fairvalue-calculator.com/stock/HSCS

Frequently asked questions

Is HeartSciences Inc. (HSCS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.79 versus a price of $2.13, about 16% lower (overvalued).
What is the fair value of HSCS?
Our estimate for HeartSciences Inc. is $1.79 (as of Nov 10, 2026), built from audited fundamentals. The current price: $2.13.
What is the quality score of HSCS?
HeartSciences Inc. has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HeartSciences Inc. (HSCS)?
Our calculated price target is the estimate of $1.79 (as of Nov 10, 2026). Cautious scenario $1.34, optimistic scenario $2.23. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the HeartSciences Inc. stock forecast for 2026?
Our estimate puts fair value at $1.79, about 16% lower versus a price of $2.13 (overvalued). Cautious scenario $1.34, optimistic scenario $2.23. The calculation is refreshed regularly with new filings.
What is the revenue of HeartSciences Inc. (HSCS)?
HeartSciences Inc. reported trailing-twelve-month revenue of about $4.5K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of HeartSciences Inc. (HSCS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HeartSciences Inc. it is $1.79 per share (as of Nov 10, 2026), against a price of $2.13.
Is HeartSciences Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, HSCS trades above its calculated fair value: price $2.13, fair value $1.79, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HSCS?
No. The price is what the market pays today ($2.13); the fair value is what the company's own numbers justify ($1.79). For HeartSciences Inc. the two are $0.3350 per share apart. That gap is exactly why we show both numbers side by side.
How much is HeartSciences Inc. worth?
The market values HeartSciences Inc. at about $10.3M (market capitalisation, as of Nov 10, 2026). Per share that is $2.13; our models calculate a fair value of $1.79 per share.
What do the bullish and bearish scenarios say about HSCS?
Our models span a range for HeartSciences Inc.: cautious scenario $1.34, base $1.79, optimistic $2.23 per share (as of Nov 10, 2026, price $2.13). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HeartSciences Inc. (HSCS)?
Balance-sheet figures for HeartSciences Inc. (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is HSCS from its 52-week high?
HeartSciences Inc. trades at $2.13, about 59% below its 52-week high of $5.20 and 27% above the low of $1.67 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $1.79 is for.
Which stocks are comparable to HeartSciences Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HeartSciences Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $2.13, calculated fair value $1.79 (−16%), Quality Score 17/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. HeartSciences Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HeartSciences Inc. (HSCS)?
The closing price on Nov 13, 2026 was $2.13. Our estimate is $1.79, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HeartSciences Inc. right now?
Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of HeartSciences Inc.

How large is the market capitalisation of HeartSciences Inc. (HSCS)?
The market capitalisation of HeartSciences Inc. is $10.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of HeartSciences Inc. (HSCS)?
Earnings per share at HeartSciences Inc. are $−3.21. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of HeartSciences Inc. (HSCS)?
The return on equity (ROE) of HeartSciences Inc. is −1,852% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HeartSciences Inc. (HSCS)?
On an EBIT basis the return on assets of HeartSciences Inc. is −135% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HeartSciences Inc. (HSCS)?
The operating margin of HeartSciences Inc. is −139,957% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HeartSciences Inc. (HSCS)?
Revenue at HeartSciences Inc. is growing 10.5% versus a year earlier (3y avg −5.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does HeartSciences Inc. (HSCS) generate?
The free cash flow of HeartSciences Inc. is −$7.5M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does HeartSciences Inc. (HSCS) carry?
The net debt of HeartSciences Inc. is $2.3B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch HeartSciences Inc. in the live analysis

One click puts HeartSciences Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.